FDA approves Recarbrio for treatment of bacterial pneumonias
Recarbrio (imipenem-cilastatin and relebactam) was approved for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).
List view / Grid view
News
Filter the results
Amneal recalls Metformin Hydrochloride Extended Release Tablets to consumer level
The voluntary recall of Metformin Hydrochloride Extended Release Tablets, 500 mg and 750 mg is due to unacceptable levels of NDMA impurities.
Gavi launches $2 billion COVID-19 vaccine funding initiative
The vaccine alliance said the Covax AMC program is the first in a series of financing programs to ensure low- and middle-income countries with have access to COVID-19 vaccines.
Lilly launches Phase I trial of investigational COVID-19 antibody treatment
The enterprise announced the initiation of the LY-CoV555 COVID-19 antibody treatment trial at medical centres across the US.
Interim analysis indicates Auxora™ is effective in severe COVID-19 pneumonia patients
Interim results showed Auxora plus standard of care improved time to recovery and reduced ventilator use in patients compared to standard of care alone.
Global regulatory authorities COVID-19 policy and regulations meeting
Global pharma regulators met to discuss measures to ensure supply continuity, flexible regulatory policies and their expectations for COVID-19 clinical trials.
COVID-19 convalescent plasma therapy shown to be safe and effective
Scientists reveal 76 percent of critically ill trial participants treated with convalescent plasma are recovering, with almost half now discharged from hospital.
Simple but effective: an experimental nanoparticle COVID-19 test
Researchers reveal their experimental test can detect the presence of COVID-19 RNA in a sample in 10 minutes, and in a way that does not require trained personnel to interpret.
Emergent to assist in production of US COVID-19 vaccine candidates
The company announces it has been task ordered by BARDA to assist in the US government’s efforts to deliver COVID-19 vaccines.
Mass spectrometry identifies biomarkers of COVID-19 disease severity
Researchers have identified 27 biomarkers that could be used to predict the course of SARS-CoV-2 infection and whether a patient with COVID-19 will become severely ill.
FDA approves CYRAMZA® (ramucirumab) for EGFR-mutated non-small cell lung cancer
CYRAMZA in combination with erlotinib was approved as a first-line treatment for metastatic EGFR-mutated non-small cell lung cancer.
60,000 doses of avifavir, a COVID-19 treatment, to be delivered in June
The Russian Direct Investment Fund (RDIF) and the ChemRar Group are to deliver the doses of avifavir, approved in Russia as a COVID-19 therapeutic, to Russian hospitals.
Lonza and Sanquin partner for commercialisation of specialised MAT reagents for accurate and reliable in vitro pyrogen testing
Lonza Sales AG, through its Bioscience Division has joined forces with Sanquin Reagents B.V. to enable drug developers and quality control laboratories to take full advantage of the power of the Monocyte Activation Test (MAT).
CDMO delivers 4000 doses of COVID-19 vaccine candidate for Phase II/III trial
Advent announced it has manufactured and delivered the first 4000 doses of the AZD1222 vaccine candidate for the University of Oxford clinical trial.
Experimental stem cell therapy trial for COVID-19 initiated
Researchers announce the first patient has been dosed in a trial testing remestemcel-L, a stem cell therapy, in severe COVID-19 patients on ventilators.